Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases

被引:60
作者
Cutuli, B
Borel, C
Dhermain, F
Magrini, SM
Wasserman, TH
Bogart, JA
Provencio, M
de Lafontan, B
de la Rochefordiere, A
Cellai, E
Graic, Y
Kerbrat, P
Alzieu, C
Teissier, E
Dilhuydy, JM
Mignotte, H
Velten, M
机构
[1] Ctr Paul Strauss, Dept Radiotherapy, F-67085 Strasbourg, France
[2] Inst Gustave Roussy, Villejuif, France
[3] Ist Radio, Brescia, Italy
[4] Mallinckrodt Inst Radiol, St Louis, MO USA
[5] Hlth Sci Ctr, Syracuse, NY USA
[6] Hop Puerta de Hierro, Madrid, Spain
[7] Ctr Claudius Regaud, Toulouse, France
[8] Inst Curie, Paris, France
[9] Univ Florence, Dept Radiotherapy, Florence, Italy
[10] Ctr Henri Becquerel, F-76038 Rouen, France
[11] Ctr Eugene Marquis, Rennes, France
[12] Inst J Paoli I Calmettes, F-13009 Marseille, France
[13] Ctr Antoine Lacassagne, F-06054 Nice, France
[14] Inst Bergonie, Bordeaux, France
[15] Ctr Leon Berard, F-69373 Lyon, France
关键词
breast cancer; Hodgkin's disease; secondary cancers; radio-induced cancers; ductal carcinoma in situ; conservative treatment;
D O I
10.1016/S0167-8140(01)00337-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods. Materials and Methods: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 1.33 BCs. The median age at diagnosis of HD was 24 years. The HD stages were stage I in 25 cases (21%), stage II in 70 casts (59%), stage III in 13 cases (11%). stage IV in six cases (5%) and not specified in five cases (4%). Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%). Results: BC occurred after a median interval of 16 years. TNM classification (UICC, 1978) showed 15 T0 (11.3%), 44 T1 (33.1%), 36 T2. (27.1%), nine T3 (6.7%), 15 T4 (11.3%) and 14 Tx (10.5%,). Ductal infiltrating carcinoma and ductal carcinoma in situ (DCIS) represented 81.2 and 11.3% of the cases, respectively. Among the infiltrating carcinoma, the axillary involvement rate was 50%. Seventy-four rumours were treated by mastectomy without (67) or with (ten) RT. Forty-four rumours had lumpectomy without (12) or with (32) RT. Another four received RT alone, and one CT alone. Sixteen patients (12%) developed isolated local recurrence. Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease. The 5-year disease-specific survival rate was 65.1%. The 5-year disease-specific survival rates for the pN0, pN1-3 and pN > 3 groups were 91, 66 and 15%, respectively (P < 0.0001). and 100, 88, and 64% for the TIS, T1 and T2. For the T3 and T4, the survival rates decreased sharply to 32 and 23%, respectively. These secondary BC are of two types: a large number of aggressive rumours with a very unfavourable prognosis (especially in the case of pN > 3 and/or T3T4), and many rumours with a 'slow spreading such as DCIS and microinvasive lesions. These lesions developed especially in patients treated exclusively by RT. Conclusions: The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography. We suggest that a baseline mammography is performed 5-8 years after supradiaphragmatic irradiation (complete mantle or involved field) in patients who were treated before 30 years of age. Subsequent mammographics should be performed every 2 years or each year. depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors. This screening seems of importance due to excellent prognosis in our T1ST1 groups, and the possibility of offering these young women a conservative treatment. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 70 条
[1]   2ND MALIGNANCIES AFTER TREATMENT OF HODGKINS-DISEASE - THE INFLUENCE OF TREATMENT, FOLLOW-UP TIME, AND AGE [J].
ABRAHAMSEN, JF ;
ANDERSEN, A ;
HANNISDAL, E ;
NOME, O ;
ABRAHAMSEN, AF ;
KVALOY, S ;
HOST, H .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :255-261
[2]  
Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO
[3]  
2-2
[4]  
ANDERSON N, 1990, CANCER, V65, P221, DOI 10.1002/1097-0142(19900115)65:2<221::AID-CNCR2820650207>3.0.CO
[5]  
2-9
[6]   SUBSEQUENT MALIGNANCIES IN CHILDREN AND ADOLESCENTS AFTER TREATMENT FOR HODGKINS-DISEASE [J].
BEATY, O ;
HUDSON, MM ;
GREENWALD, C ;
LUO, XL ;
FANG, L ;
WILIMAS, JA ;
THOMPSON, EI ;
KUN, LE ;
PRATT, CB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :603-609
[7]   Breast cancer and other second neoplasms after childhood Hodgkin's disease [J].
Bhatia, S ;
Robison, LL ;
Oberlin, O ;
Greenberg, M ;
Bunin, G ;
FossatiBellani, F ;
Meadows, AT .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :745-751
[8]   2ND SOLID TUMORS AND LEUKEMIA AFTER TREATMENT FOR HODGKINS-DISEASE - AN ANALYSIS OF 1121 PATIENTS FROM A SINGLE INSTITUTION [J].
BITI, G ;
CELLAI, E ;
MAGRINI, SM ;
PAPI, MG ;
PONTICELLI, P ;
BODDI, V .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01) :25-31
[10]   INCIDENCE OF 2ND CANCERS IN PATIENTS TREATED FOR HODGKINS-DISEASE [J].
BOIVIN, JF ;
HUTCHISON, GB ;
ZAUBER, AG ;
BERNSTEIN, L ;
DAVIS, FG ;
MICHEL, RP ;
ZANKE, B ;
TAN, CTC ;
FULLER, LM ;
MAUCH, P ;
ULTMANN, JE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (10) :732-741